MedPath

China National Biotec Group Company Limited

πŸ‡¨πŸ‡³China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

35

Active:7
Completed:11

Trial Phases

3 Phases

Phase 1:1
Phase 3:7
Phase 4:27

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (35 trials with phase data)β€’ Click on a phase to view related trials

Phase 4
27 (77.1%)
Phase 3
7 (20.0%)
Phase 1
1 (2.9%)

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Phase 3
Active, not recruiting
Conditions
Varicella
First Posted Date
2023-05-03
Last Posted Date
2023-06-18
Lead Sponsor
China National Biotec Group Company Limited
Target Recruit Count
1200
Registration Number
NCT05839301
Locations
πŸ‡¨πŸ‡³

Xinyi Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Phase 3
Active, not recruiting
Conditions
Varicella
First Posted Date
2023-01-03
Last Posted Date
2023-06-18
Lead Sponsor
China National Biotec Group Company Limited
Target Recruit Count
12440
Registration Number
NCT05669625
Locations
πŸ‡¨πŸ‡³

Sinan County Center for Disease Control and Prevention, Tongren, Guizhou, China

πŸ‡¨πŸ‡³

Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China

πŸ‡¨πŸ‡³

Yuping Dong Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China

and more 10 locations

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Phase 4
Conditions
Hemolysis
COVID-19
First Posted Date
2022-07-29
Last Posted Date
2022-08-30
Lead Sponsor
China National Biotec Group Company Limited
Target Recruit Count
1200
Registration Number
NCT05480436
Locations
πŸ‡¨πŸ‡³

Xiangya Hospital Central South University, Changsha, China

πŸ‡¨πŸ‡³

Sichuan Center for Disease Control and Prevention, Chengdu, China

πŸ‡¨πŸ‡³

Guizhou Center for Disease Control and Prevention, Guiyang, China

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Phase 4
Conditions
COVID-19
Rabies
First Posted Date
2022-07-12
Last Posted Date
2022-07-29
Lead Sponsor
China National Biotec Group Company Limited
Target Recruit Count
360
Registration Number
NCT05453487
Locations
πŸ‡¨πŸ‡³

Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China

πŸ‡¨πŸ‡³

Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

Phase 3
Active, not recruiting
Conditions
COVID-19
First Posted Date
2022-05-19
Last Posted Date
2023-06-18
Lead Sponsor
China National Biotec Group Company Limited
Target Recruit Count
1804
Registration Number
NCT05382871
Locations
πŸ‡­πŸ‡°

Queen Mary Hospital, Hong Kong, Hong Kong

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.